

---

# Current Opinion in Drug Discovery & Development

## Contents

- 407 Paper alert**  
Peter Norman, David P Rotella & Brad Sherborne
- 421 Patent alert**  
Thomson Reuters Current Awareness Analysts
- 434 Web alert**  
Thomas DY Chung
- The Chemistry of Drug Design and Lead Optimization**  
Edited by Manoj C Desai & Samuel Chackalamannil
- Editorial overview**
- 436 Rediscovering the role of natural products in drug discovery**  
Manoj C Desai & Samuel Chackalamannil
- Reviews**
- 438 Agonists of the serotonin 5-HT<sub>2c</sub> receptor: Preclinical and clinical progression in multiple diseases**  
Dean A Wacker & Keith J Miller
- 446 Recent progress in the discovery of selective, non-peptide ligands of somatostatin receptors**  
Scott E Wolkenberg & Catherine J Thut
- 458 Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: The development pipeline and recent clinical data**  
Zachary K Sweeney & Klaus Klumpp
- 471 Integrase inhibitors for the treatment of HIV infection**  
Paola Pace & Michael Rowley
- 480 TAFIa inhibitors in the treatment of thrombosis**  
Mark E Bunnage & Dafydd R Owen
- 487 Targeting myostatin for therapies against muscle-wasting disorders**  
Kunihiro Tsuchida
- 495 Recent advances in the discovery of 11 $\beta$ -HSD1 inhibitors**  
Craig D Boyle
- 512 From the bench to the bedside: Dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents**  
Zhonghua Pei
- 533 Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic**  
Miguel Medina & Ana Castro
- 544 Conformationally based design of macrocycles as antitumor agents**  
Erinprit K Singh, Robert P Sellers, Leslie D Alexander & Shelli R McAlpine
- 553 The impact of diversity-based, high-throughput screening on drug discovery: "Chance favours the prepared mind"**  
Michael Snowden & Darren VS Green
- 559 From virtuality to reality – Virtual screening in lead discovery and lead optimization: A medicinal chemistry perspective**  
Ulrich Rester
- 569 Exploiting QSAR models in lead optimization**  
Peter Gedeck & Richard A Lewis